Cochrane Review Group

Kidney and Transplant

139 systematic reviews in Kidney and Transplant ask 2,434 questions. 20.7% have no studies to answer them, 25.1% rest on very low certainty evidence and 20.1% reach moderate or high certainty.

Reviews

139

Questions

2,434

current versions

No studies

20.7%

Moderate or high

20.1%

No studies 504 · 20.7%Ungraded 40 · 1.6%Very low 611 · 25.1%Low 790 · 32.5%Moderate 414 · 17%High 75 · 3.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Kidney and Transplant

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Valaciclovir vs ganciclovir or valganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.91 [0.22, 3.73]	3 studies · 271 participants	Very low
Low vs standard dose valganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Low vs standard dose valganciclovir Adverse events · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs placebo or no treatment Death (any cause) · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of haematuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Death (any cause) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Relapse of haematuria (macroscopic) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 1.33 [0.8, 2.23]	1 study · 32 participants	Very low

Reviews 139

Immunosuppressive agents for treating IgA nephropathy

Natale, P, Palmer, SC, et al. · Cochrane Database of Systematic Reviews · 2020

Kidney and Transplant

Thinnest evidence

Reviews 139

Immunosuppressive agents for treating IgA nephropathy

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients

Calcium channel blockers for people with chronic kidney disease requiring dialysis

Interventions for itch in people with advanced chronic kidney disease

Pharmacological interventions for heart failure in people with chronic kidney disease

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy

Oral protein‐based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis

Urgent‐start peritoneal dialysis versus conventional‐start peritoneal dialysis for people with chronic kidney disease

Potassium binders for chronic hyperkalaemia in people with chronic kidney disease

Perioperative antibiotics for preventing post‐surgical site infections in solid organ transplant recipients

Interventions for primary vesicoureteric reflux

Long‐term antibiotics for preventing recurrent urinary tract infection in children

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients

Psychosocial interventions for preventing and treating depression in dialysis patients

Catheter type, placement and insertion techniques for preventing catheter‐related infections in chronic peritoneal dialysis patients

Interventions for preventing bone disease in kidney transplant recipients

Parenteral versus oral iron therapy for adults and children with chronic kidney disease

Human albumin infusion for treating oedema in people with nephrotic syndrome

Low dialysate sodium levels for chronic haemodialysis

Machine perfusion preservation versus static cold storage for deceased donor kidney transplantation

eHealth interventions for people with chronic kidney disease

Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis

Interventions for improving sleep quality in people with chronic kidney disease